ReviewInternational journal of molecular sciences2026
The "Double-Edged Sword" of Neutrophils in Trauma: From Pathophysiological Mechanisms to Precision Immunomodulation Strategies.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Neutrophils occupy a central yet paradoxical position in post-trauma immunity, functioning as both sentinels of host defense and mediators of tissue damage. This review comprehensively examines the spatiotemporal dynamics of neutrophil biology after trauma, ranging from recruitment and effector functions to diverse cell death modalities. We detail how aberrant activation mechanisms, specifically oxidative burst, protease release, and neutrophil extracellular trap formation fuel systemic inflammation, immunothrombosis, and remote organ injury. We also discuss the neutrophil dysfunction-induced immunosuppression and barriers to tissue regeneration. Mechanistically, we dissect the regulatory networks involving NF-κB/MAPK signaling, non-coding RNAs, extracellular vesicles, and metabolic reprogramming. On the clinical front, we evaluate emerging biomarkers and precision therapeutics, such as CXCR2 antagonists and neutrophil extracellular traps inhibitors, designed to recalibrate rather than ablate neutrophil function to balance host defense and tissue repair. We conclude by outlining a future roadmap that leverages single-cell multi-omics and AI to resolve neutrophil heterogeneity and advance personalized interventions for trauma patients.
Indexed as
Identifiers
42794520What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.